Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Non-Current Debt (2022 - 2025)

Cue Biopharma (CUE) has disclosed Non-Current Debt for 4 consecutive years, with $190000.0 as the latest value for Q3 2025.

  • Quarterly Non-Current Debt fell 85.69% to $190000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $190000.0 through Sep 2025, down 85.69% year-over-year, with the annual reading at $4.2 million for FY2023, 47.7% down from the prior year.
  • Non-Current Debt hit $190000.0 in Q3 2025 for Cue Biopharma, roughly flat from $190000.0 in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $9.9 million in Q2 2022 to a low of $190000.0 in Q2 2025.
  • Historically, Non-Current Debt has averaged $5.1 million across 4 years, with a median of $5.2 million in 2023.
  • Biggest five-year swings in Non-Current Debt: dropped 28.23% in 2023 and later tumbled 91.69% in 2025.
  • Year by year, Non-Current Debt stood at $8.0 million in 2022, then tumbled by 47.7% to $4.2 million in 2023, then tumbled by 68.4% to $1.3 million in 2024, then crashed by 85.69% to $190000.0 in 2025.
  • Business Quant data shows Non-Current Debt for CUE at $190000.0 in Q3 2025, $190000.0 in Q2 2025, and $1.3 million in Q3 2024.